This question was asked by Goldman Sachs analysts in April of 2018, according to CNBC: “Is curing patients a sustainable business model?” “Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering ‘gene therapy’ treatment: cures could be bad for business in the long run.